2-AG (2-Arachidonoylglycerol): The Body's Other Main Endocannabinoid

Where the name comes from

2-AG stands for 2-arachidonoylglycerol. Long word, plain construction. Take a glycerol backbone, number its three positions, and attach one molecule of arachidonic acid at the middle one. That middle position is number 2. So the 2 sits at the front of the name, and the rest follows: arachidonoyl for the fatty acid, glycerol for what it sits on. Chemically it belongs to a familiar family, an ester on glycerol, the same basic arrangement found in ordinary fats and oils.

The standing is just as simple to state. 2-AG is the second major endocannabinoid, described alongside anandamide. Second in the order of description, though, not second in amount. Measured in body tissue, 2-AG is the more plentiful of the pair.

One word is worth unpacking here. Endocannabinoids are cannabinoids the body builds itself, assembled from fatty acid building blocks. That puts 2-AG in a different box from the cannabinoids most people read about. It is not a plant compound. It is not an ingredient. You will not see it on the composition of a hemp extract, because the plant does not make it and no extraction step could put it there. It is made in the body, acts in the body, and is broken down in the body.

Keeping that line clear matters. A lot of the muddle around this subject starts with one mix-up: compounds made by a plant, compounds made by a person. The two share a receptor system. They do not share an origin, and they do not appear in the same places.

Found twice in the same year

By the mid-1990s the question had an obvious shape. Anandamide had been described in 1992, the first molecule shown to be produced in the body and to fit the cannabinoid receptors. One molecule for a whole receptor system looked thin. So the follow-up was blunt. If the body makes one, does it make others?

Two groups went looking. They looked in two different tissues, and they landed on the same compound.

Mechoulam and colleagues reported in 1995 on an endogenous 2-monoglyceride isolated from gut tissue, and showed that it bound to the cannabinoid receptors [1]. Digestive tissue, not nervous tissue. The second route ran through the brain. In the same year, Sugiura and colleagues identified 2-arachidonoylglycerol in brain and put it forward as a possible endogenous ligand for the cannabinoid receptor [2].

Two teams. Two tissues. One compound. One calendar year.

That kind of convergence tends to settle a question quickly. Neither report needed the other to make its case, and the two together left little room for doubt that the molecule was really there and really binding. Since then, 2-AG has turned up in nearly every serious description of the signalling system. It is hard to find a careful account that leaves it out.

Worth noting what the early work actually consisted of. Not grand claims. Careful measurement, in defined tissue, with the identity of the compound pinned down first. The groundwork was analytical, and it is the reason later work had something solid to build on. Two papers, published within months of each other, still doing the job three decades later.

The pair, and the enzyme

The most useful detail about 2-AG is a comparison. Put it next to anandamide and the picture sharpens. Both are endocannabinoids. Both are built in the body from fatty acid material. The concentrations differ, and not by a little: 2-AG is present at higher levels than anandamide. That difference in scale has a practical consequence, because a compound present in larger amounts is easier to detect and quantify. A good deal of measurement work has gone into 2-AG for exactly that reason.

Then the receptor profile. 2-AG acts as a full agonist at both CB1 and CB2, the two principal cannabinoid receptors. Full activation, not partial. That is a specific pharmacological description, and it gives the molecule a second role in the literature: a reference point. When other compounds are tested at those same two receptors, including plant-derived cannabinoids, 2-AG is one of the yardsticks they get compared against.

Clearance has a name too. The main enzyme that breaks 2-AG down is monoacylglycerol lipase. Made, used, removed, with a named route out.

We have been working with cannabinoids since 2014, and in that time we have watched claims about this particular molecule run ahead of the data more than once. So it is worth being exact about what is documented and what is not. Identity, structure, distribution across tissues, clearance route: all well described. What a given amount of anything does to those numbers in a person, and what that would mean, is a separate question, and the two 1995 papers were never written to answer it.

The record, row by row

Everything above, compressed into one place. The right-hand column shows which of the two cited works a given line comes from, where a source applies. Lines without a marker are descriptive chemistry or naming convention rather than a finding from either paper.